Zacks Investment Research upgraded shares of IRIDEX (NASDAQ:IRIX) from a sell rating to a hold rating in a report released on Wednesday morning, Zacks.com reports.

According to Zacks, “IRIDEX Corporation is the leading worldwide provider of semiconductor-based laser systems used to treat eye diseases in ophthalmology and skin lesions in dermatology. The products are sold in the United States predominantly through a direct sales force and internationally through independent distributors. The company markets the products using three brand names: IRIS Medical to the ophthalmology market, IRIDERM to the dermatology market, and Light Solutions to the research market. “

Separately, ValuEngine raised shares of IRIDEX from a hold rating to a buy rating in a research report on Tuesday, January 5th.

NASDAQ:IRIX opened at $5.12 on Wednesday. IRIDEX has a one year low of $1.22 and a one year high of $5.29. The company has a market cap of $71.16 million, a P/E ratio of -9.31 and a beta of 1.09. The firm’s fifty day moving average price is $2.10 and its two-hundred day moving average price is $2.02. The company has a debt-to-equity ratio of 0.06, a current ratio of 2.77 and a quick ratio of 2.01.

IRIDEX (NASDAQ:IRIX) last announced its earnings results on Monday, November 9th. The medical equipment provider reported ($0.12) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.18) by $0.06. The company had revenue of $8.80 million during the quarter, compared to analysts’ expectations of $7.79 million. IRIDEX had a negative net margin of 21.54% and a negative return on equity of 38.60%. As a group, equities research analysts expect that IRIDEX will post -0.56 earnings per share for the current year.

An institutional investor recently raised its position in IRIDEX stock. Isthmus Partners LLC increased its position in shares of IRIDEX Co. (NASDAQ:IRIX) by 5.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 227,582 shares of the medical equipment provider’s stock after purchasing an additional 10,913 shares during the quarter. Isthmus Partners LLC owned 1.64% of IRIDEX worth $446,000 at the end of the most recent reporting period. Institutional investors own 32.32% of the company’s stock.

IRIDEX Company Profile

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.

Recommended Story: Capital Gains

Get a free copy of the Zacks research report on IRIDEX (IRIX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.